Winston Pharmaceuticals, Inc.
Winston Pharmaceuticals, Inc.
Your view on WPHM
Overview
What the company does, where it operates, and who runs it.
About Winston Pharmaceuticals, Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Joel E. Bernstein
- Headquarters
- 100 North Fairway Drive, Vernon Hills, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Joel E. Bernstein
- Headquarters
- 100 North Fairway Drive, Vernon Hills, US
Winston Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and commercializes therapeutics for pain management.
It focuses on pain indications, such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo-and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease, as well as niche indications.
Winston Pharmaceuticals, Inc. was formerly known as Winston Laboratories, Inc. and changed its name to Winston Pharmaceuticals, Inc. in November 2008. The company was incorporated in 1998 and is headquartered in Vernon Hills, Illinois.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Winston Pharmaceuticals, Inc., and the rating behind it. WPHM last traded at $0.0003; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Winston Pharmaceuticals, Inc.. Starting points for Winston Pharmaceuticals, Inc.: EPS -$0.04, beta -982.38 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Winston Pharmaceuticals, Inc.. Winston Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Winston Pharmaceuticals, Inc.. Trailing twelve-month EPS for Winston Pharmaceuticals, Inc. stands at -$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Winston Pharmaceuticals, Inc.. Winston Pharmaceuticals, Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Winston Pharmaceuticals, Inc. valued side by side against its closest peers. Winston Pharmaceuticals, Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Winston Pharmaceuticals, Inc., and how their positions are changing. At a $23,223 market value, institutional positions materially move Winston Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Winston Pharmaceuticals, Inc. executives and directors. Shares of Winston Pharmaceuticals, Inc. have traded between $0.0001 and $0.0003 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Winston Pharmaceuticals, Inc.. Winston Pharmaceuticals, Inc. is a $23,223 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Winston Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Winston Pharmaceuticals, Inc.. Coverage tracks Winston Pharmaceuticals, Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.